Generation Bio’s (GBIO) “Buy” Rating Reiterated at Needham & Company LLC

Needham & Company LLC reaffirmed their buy rating on shares of Generation Bio (NASDAQ:GBIO) in a report published on Friday morning,Benzinga reports. They currently have a $15.00 price objective on the stock.

A number of other research analysts also recently issued reports on GBIO. Wall Street Zen downgraded Generation Bio from a “hold” rating to a “sell” rating in a report on Saturday, July 26th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Generation Bio in a research report on Wednesday, October 8th. Canaccord Genuity Group upped their target price on Generation Bio from $9.00 to $10.00 and gave the company a “buy” rating in a report on Monday, August 18th. Finally, Wedbush lowered Generation Bio from an “outperform” rating to a “neutral” rating and set a $7.00 price target for the company. in a research note on Wednesday, August 13th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Generation Bio presently has a consensus rating of “Hold” and an average target price of $10.67.

Generation Bio Price Performance

GBIO traded up $0.36 during trading on Friday, hitting $5.47. 100,490 shares of the stock traded hands, compared to its average volume of 144,516. The firm has a market capitalization of $36.87 million, a P/E ratio of -0.59 and a beta of 2.51. Generation Bio has a 12-month low of $3.00 and a 12-month high of $23.80. The firm has a 50-day moving average of $5.95 and a 200 day moving average of $4.89.

Generation Bio (NASDAQ:GBIO) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($0.82) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.18) by $2.36. The business had revenue of $1.59 million for the quarter, compared to analyst estimates of $0.66 million. Generation Bio had a negative net margin of 410.13% and a negative return on equity of 94.82%. As a group, equities analysts predict that Generation Bio will post -1.75 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. AQR Capital Management LLC purchased a new position in Generation Bio in the 1st quarter worth about $36,000. Marshall Wace LLP bought a new stake in shares of Generation Bio in the second quarter worth approximately $37,000. Y Intercept Hong Kong Ltd bought a new stake in shares of Generation Bio in the second quarter worth approximately $47,000. Nuveen LLC purchased a new position in shares of Generation Bio during the first quarter valued at approximately $69,000. Finally, Acadian Asset Management LLC lifted its position in Generation Bio by 54.3% during the first quarter. Acadian Asset Management LLC now owns 1,159,135 shares of the company’s stock valued at $468,000 after purchasing an additional 407,843 shares during the period. 95.22% of the stock is currently owned by institutional investors.

Generation Bio Company Profile

Generation Bio Co develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems.